ANVS
ANVS
NYSE · Biotechnology

Annovis Bio

$2.23
+0.00 (+0.00%)
As of Apr 1, 3:25 PM ET ·
Financial Highlights (FY 2025)
Revenue
18.60M
Net Income
-5,133,777
Gross Margin
29.4%
Profit Margin
-27.6%
Rev Growth
+22.8%
D/E Ratio
0.56
Revenue & Net Income
Margin Trends
FY 2025 FY 2024 FY 2023
Gross Margin 29.4% 29.4% 29.4%
Operating Margin -25.7% -23.2% -22.1%
Profit Margin -27.6% -28.9% -22.2%
Income Statement
FY 2025 FY 2024 FY 2023
Revenue 18.60M 19.31M 20.88M
Gross Profit 5.47M 5.68M 6.14M
Operating Income -4,787,256 -4,482,281 -4,618,990
Net Income -5,133,777 -5,587,628 -4,631,912
Gross Margin 29.4% 29.4% 29.4%
Operating Margin -25.7% -23.2% -22.1%
Profit Margin -27.6% -28.9% -22.2%
Rev Growth +22.8% -8.3% +12.1%
Balance Sheet
FY 2025 FY 2024 FY 2023
Total Debt 18.30M 16.57M 18.68M
Total Equity 32.76M 33.74M 31.53M
D/E Ratio 0.56 0.49 0.59
Cash Flow
FY 2025 FY 2024 FY 2023
EBITDA -5,451,350 -5,303,939 -6,015,367
Free Cash Flow -4,165,501 -4,081,500 -5,685,079